Good morning, everyone, and how are you today? We are doing just fine, thank you. Given that this is already the middle of the week and we have survived this far, there is no reason not to continue, yes? Just consider the alternatives. In fact, this modest accomplishment calls for celebration. So please join us in quaffing a ritual cup of needed stimulation. Our choice today is cinnamon hazelnut. Or grab a bottle of water, if you prefer. Meanwhile, here are a few items of interest to help you along. Once again, we hope you have a successful day and, of course, keep in touch. We enjoy hearing your tips and tidbits. …
Moderna chair Noubar Afeyan launched an unflinching defense of the board’s executive hiring process after it was forced to fire its new chief financial officer last week following just one day in the job, The Financial Times tells us. Afeyan dismissed suggestions the board could have done anything differently, insisting it had asked all the right questions but was not told about an internal investigation into financial reporting at Jorge Gomez’s former employer due to legal constraints. Afeyan said the executive search company contracted by Moderna was also blameless because it was unaware of the probe by dental equipment maker Dentsply Sirona, which was disclosed last week.
A clutch of serious challenges — high prices, a lack of effective combination pills, and a failure to register some medicines with government authorities — has restricted access to many high blood pressure drugs in a sample of low- and middle-income countries, STAT writes, citing a new analysis. As a result, the ability to control a widespread medical condition that is a risk factor for the leading cause of death worldwide is being hindered. The analysis noted that nearly three-quarters of all people who have high blood pressure live in low- and middle-income countries, but less than 10% are effectively treated.
Create a display name to comment
This name will appear with your comment